Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
-
VivoPower’s Tembo e-LV Subsidiary on Track for $200 Million Enterprise Value Investment from Energi Holdings via SPAC Transaction
-
Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.
-
Ocean Power Technologies Expands U.S. Presence with New Washington, D.C. Office at AUVSI Headquarters
-
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
-
AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority
-
FTC Solar to Participate in Upcoming Investor Events
-
American Rare Earths Announces: Test Mining Commences To Extract Feedstock for Demonstration Plant at The Cowboy State Mine
-
SAMBAZON Announces Ten-Store Agreement for Cincinnati Market
-
SUNation Energy Announces 2025 Second Quarter Results and Reiterates Full Year Financial Guidance
-
Notice on the convened Extraordinary General Meeting of Shareholders of AB “KN Energies”
-
Sable Completes VTEM Geophysical Survey at the Copper Queen Project in British Columbia
-
Sharc Energy Completes $1.57 Million Unsecured Debenture
-
SONORO GOLD PROVIDES SURFACE RIGHTS UPDATE FOR THE CERRO CALICHE GOLD PROJECT
-
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
-
OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer
-
IBN Announces Latest Episode of The GotStocks Podcast featuring Matthew McGahan, CEO of SEGG Media Corp.
-
Critical Metals Corp Reports Extremely High-Grade Drilling Results From its 2024 Program: 103 PPM Gallium & rare earth elements of 27.0% HREO & TREO Range 0.48% to 0.55% & Zirconium Oxide
-
DeFi Development Corp. to Participate in the Lytham Partners 2025 Consumer & Technology Investor Summit on August 19, 2025
-
Applied Digital to Break Ground on $3 Billion Polaris Forge 2 Campus in September 2025, Expanding North Dakota’s Role as a National AI Infrastructure Leader
-
AI SEO Consultant Olga Zarr’s Stance on AI and SEO in 2025: 90% Fundamentals, 10% AI
-
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
-
Cuprina Reaffirms Commitment to Shareholders and Patients Following Recent Stock Market Activity
-
The Oncology Institute and Doctors Healthcare Plans Partner to Elevate Oncology Care Management in South Florida
-
Lotus Technology to Report Unaudited First Half 2025 Financial Results on August 29, 2025
-
Rezolve Ai Celebrates One Year Anniversary of Nasdaq Listing with Explosive Growth, $70M+ ARR, and Global Expansion
-
YY Group Launches AI-Powered Customer Service and Expands into AI Recruitment Platform
-
Catheter Precision Receives Approval for LockeT in the United Kingdom
-
Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + Energy
-
Treatment.com AI Inc. to Rebrand as Rocket Doctor AI Inc., Aligning Business with Evolving Product Portfolio and Market Strategy
-
Eos Energy Enterprises Appoints Industry Veteran John Mahaz as Chief Operating Officer to Drive Next Phase of Operational Growth in American-Made Energy Storage
-
Equus Announces Second Quarter Net Asset Value
-
Critical Metals Corp Reports Extremely High-Grade Drilling Results From its 2024 Program: 103 PPM Gallium & rare earth elements of 27.0% HREO & TREO Range 0.48% to 0.55% & Zirconium Oxide of 1.99% Fr
-
DeFi Development Corp. to Participate in the Lytham Partners 2025 Consumer & Technology Investor Summit on August 19, 2025
-
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
-
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
-
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
-
Alpha Modus Agrees to Preferred Stock Exchange to Eliminate ~$41 Million in Mezzanine Equity, Strengthening Balance Sheet, and Fully Aligning Insider Interests
-
Real Career Mode FC Launches Fan-Driven Football Club Ownership Model
-
LIXTE Biotechnology Holdings Provides Corporate Update
-
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
-
Nuvini Group Unveils New Leadership Incentive Plan, Underscoring Commitment to Shareholders
-
Optex Systems to Present at the 2025 Gateway Conference on September 4
-
Aditude Appoints Anthony Gonsalves as First Chief Revenue Officer
-
Hepsiburada Announces Ordinary General Assembly Meeting for Financial Year 2024
-
Schouw & Co. share buy-back programme, week 33 2025
-
STMicroelectronics Announces Status of Common Share Repurchase Program
-
JDE Peet’s share buyback periodic update August 18, 2025
-
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
